A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme | Zendy

Craig B. Langman | Zendy; Danica Grujić | Zendy; R.M. Pease | Zendy; Linda Easter | Zendy; J. Nezzer | Zendy; Alexey L. Margolin | Zendy; Lee Brettman | Zendy

Open Access

A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme

Author(s) -

Craig B. Langman,

Danica Grujić,

R.M. Pease,

Linda Easter,

J. Nezzer,

Alexey L. Margolin,

Lee Brettman

Publication year - 2016

Publication title -

american journal of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 85

eISSN - 1421-9670

pISSN - 0250-8095

DOI - 10.1159/000448766

Subject(s) - oxalate , excretion , medicine , placebo , calcium oxalate , endocrinology , urinary system , kidney stones , chemistry , pathology , alternative medicine , organic chemistry

Hyperoxaluria may result from increased endogenous production or overabsorption of dietary oxalate in the gastrointestinal tract leading to nephrolithiasis and, in some, to oxalate nephropathy and chronic kidney disease. ALLN-177 is an oral formulation of a recombinant, oxalate specific, microbial enzyme oxalate decarboxylase intended to treat secondary hyperoxaluria by degrading dietary oxalate in the gastrointestinal tract, thereby reducing its absorption and subsequent excretion in the urine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research